ArticlePathogens and global health2022
A tentative assessment of the changes in transmissibility and fatality risk associated with Beta SARS-CoV-2 variants in South Africa: an ecological study.
Article in Pathogens and global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19.Diagnostics (Basel, Switzerland) · 2023Review
- Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate.International journal of environmental research and public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The circulation of SARS-CoV-2 Beta (B.1.351) variants challenged the control of COVID-19 pandemic. The numbers of COVID-19 cases and deaths and SARS-CoV-2 sequences in South Africa were collected. We reconstructed the variant-specified reproduction numbers (R t) and delay-adjusted case fatality ratio (CFR) to examine the changes in transmissibility and fatality risk of Beta over non-Beta variants. We estimated that Beta variants were 41% (95%CI: 16, 73) more transmissible and 53% (95%CI: 6, 108) more fatal than non-Beta variants. Higher risks of infection and fatality might lead to increasing volumes of infections and critical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.